Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405844 | 0.78 | PTGDR2 (0.41) | ALDH1A1ALDH1A3ALDH3A1HTTLMNA | |
| SCHEMBL3631166 | 0.77 | ALDH1A3 (0.52) | ALDH1A1HPGDKMT2AALDH1A3ALDH3A1 | |
| SCHEMBL11292175 | 0.76 | MEN1 (0.43) | ALDH1A1KMT2AALDH1A3ALDH3A1LMNA | |
| SCHEMBL5692404 | 0.74 | POLB (0.58) | ALDH1A1HTTKDM4ETSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1596701 | 0.73 | POLB (0.57) | ALDH1A1HTTKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL7509476 | 0.72 | ALDH1A1 (0.50) | ALDH1A1HPGDKMT2AHTTKDM4E | |
| SCHEMBL27895961 | 0.72 | ALDH1A3 (0.46) | ALDH1A1HPGDKMT2AALDH1A3ALDH3A1 | |
| SCHEMBL15331292 | 0.71 | TSHR (0.47) | ALDH1A1HPGDKMT2AALDH1A3LMNA | |
| SCHEMBL3466337 | 0.70 | DRD1 (0.49) | ALDH1A1HPGDALDH1A3ALDH3A1HTT | |
| SCHEMBL29654951 | 0.70 | DRD1 (0.49) | ALDH1A1HPGDALDH1A3ALDH3A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | ALDH1A1 2196/4885HPGD 674/4885KMT2A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.